Skip to main content
. 2020 Feb 18;11:223. doi: 10.3389/fimmu.2020.00223

Figure 3.

Figure 3

A personalized pre-treatment strategy to optimize outcomes to immune checkpoint blockade. We propose a pre-treatment approach to treating cancer patients, where tumors displaying features of a non-responsive TME can be first sensitized to attain a favorable TME, to improve chances of response to immune checkpoint blockade. Figures made in ©BioRender-biorender.com. Adapted from a figure we published recently in Science Translational Medicine (7).